|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
Moreover, the combinational therapy of these agents might promisingly improve the clinical efficacy of TRAIL in patients with AML.
|
30589076 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
TNF-related apoptosis-inducing ligand (TRAIL) and its receptors are frequently deregulated in AML patients and their targeting may represent a promising strategy for development of new treatments.
|
30813354 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
A combination of RO-BIR2 with TNF-related apoptosis-inducing ligand (TRAIL) led to highly synergistic effect on AML cell lines and AML patient samples.
|
29063676 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
Overall, we propose that miR-424&27a and/or PLAG1 might serve as novel therapeutic targets in AML TRAIL therapy.
|
27013583 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
Cotreatment with the apoptosis-inducing cytokine TRAIL did not enhance cell death in CD34(+) AML cells, in contrast to the effects in AML cell lines.
|
23416210 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.
|
23046813 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.
|
23492767 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the combined treatment of nutlin-3 plus TRAIL might offer a novel therapeutic strategy for AML.
|
17504227 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
|
12780785 |
2003 |
|
Leukemia, Myelocytic, Acute
|
0.390 |
Biomarker
|
disease |
BEFREE |
Moreover, the dichotomous effect of TRAIL on malignant cells (early induction of apoptosis and monocytic maturation of the surviving cells) might have important therapeutic implications for the treatment of acute myeloid leukemia.
|
12239152 |
2002 |